The organization launched its GOBOLDLY campaign to highlight the work of US biopharmaceutical companies.
On Jan. 23, 2017 the Pharmaceutical Research and Manufacturers of America (PhRMA) announced the launch of a multi-year advertising and public affairs initiative on behalf of US biopharmaceutical companies. The campaign is titled GOBOLDLY and will include national television, print, digital, radio and out-of-home advertising focused on highlighting the work of biopharmaceutical companies.
According to PhRMA, the ad campaign highlights revolutionary biopharmaceutical science. The first television advertisement in the campaign features the Dylan Thomas poem Do Not Go Gentle. In addition to paid advertising, the campaign will include public affairs activities to foster a national dialogue with researchers, caregivers, patients, and policymakers in forums around the country. These discussions will focus on what the new era in medicine means for patients and the health care system and the types of public policy solutions that are needed to sustain progress.
“Through partnerships and collaborations with other health care leaders, we will work to advance commonsense solutions that foster the continued development of new medicines, enhance the private marketplace and provide patients with access to the newest and most innovative treatments,” said Stephen J. Ubl, president and CEO of PhRMA, in a statement.
The campaign will include three distinct public affairs initiatives around the following core areas: bold advancements in science, value-driven health care, and public health. These efforts will officially kick off in February and March 2017.
Source: PhRMA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.